General Announcement::PRESS RELEASE - END-OF-PHASE 2 MEETING WITH THE U.S. FDA REGARDING WAFERMINE

Issuer & Securities

Issuer/ Manager
IX BIOPHARMA LTD.
Securities
IX BIOPHARMA LTD. - SG1BD9000009 - 42C
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
10-Dec-2019 17:30:14
Status
New
Announcement Sub Title
PRESS RELEASE - END-OF-PHASE 2 MEETING WITH THE U.S. FDA REGARDING WAFERMINE
Announcement Reference
SG191210OTHRC1QY
Submitted By (Co./ Ind. Name)
Lee Wei Hsiung
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Please refer to the attachment.

Attachments

Press Release - End of Phase 2 Meeting 101219.pdf
Total size =169K